Drug Trial Radar · NCT07272902
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Nova Scotia Health AuthorityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Heart and Stroke Foundation of Canada
- First posted
- Dec 9, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase will determine if a larger study can be successfully carried out to see which approach better improves survival, reduces hospitalizations, and enhances quality of life.
Conditions
- Atrial Fibrillation (AF)
- Heart Failure With Mildly Reduced Ejection Fraction
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Rate Control
- Rhythm Control
Interventions
Catheter Ablation for Atrial FibrillationProcedure
Participants randomized to this arm will undergo catheter ablation within 4 weeks of randomization. Pulmonary vein isolation is required; additional ablation strategies may be applied at investigator discretion. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.
Rate Control Medications (beta-blockers, calcium channel blockers, digoxin)Drug
Participants randomized to this arm will receive pharmacologic therapy to achieve guideline-recommended heart rate control (resting HR \<80 bpm, \<110 bpm with exercise). Therapy may include beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. If adequate control is not achieved with medication, AV nodal ablation and pacing may be used. Guideline-directed medical therapy for atrial fibrillation and heart failure will also be provided.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of Trial ConductTime frame: 12 months after randomization
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
QEII HSC
Halifax, Nova Scotia, Canada · Recruiting
Hamilton Health Sciences
Hamilton, Ontario, Canada · Recruiting
London Health Sciences Centre
London, Ontario, Canada · Recruiting
Montreal Heart Institute
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.